TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01651104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)
Description: A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
Study: NCT02794818

Intervention type: BEHAVIORAL
Intervention: Produce boxes with nutritional education
Description: CSA produce boxes prescribed to study participants with free online nutritional education included
Study: NCT00404820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg solution
Description: Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate 70 mg tablets
Description: Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium/Vitamin D
Description: Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium/Vitamin D
Description: Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
Study: NCT04968041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program
Description: The intervention using strategies from motivational interviewing and cognitive behavioral therapy to promote motivation and adherence to ketogenic nutrition in older adults at high risk for Alzheimer's disease. The program is a 6-week, group program led by a psychologist and nutrition expert.
Study: NCT03712748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure therapy
Description: All participants will complete the same arm, which is four sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
Study: NCT03846570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol-beclomethasone
Description: formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (identically package) administered BID
Study: NCT01573871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Hydrolyzed infant formula
Description: Experimental hydrolyzed infant formula to be fed ad libitum
Study: NCT02456597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocainhydrochlorid
Description: Lidocaine injected through the novel Catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: Isotonic saline injected through the novel Catheter
Study: NCT01377025

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tablets in the morning and two in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg Sorafenib bid until PD if staging after Run-In was PR or CR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg Sorafenib bid until PD if staging after Run-In was SD
Study: NCT00575536

Intervention type: PROCEDURE
Intervention: Rhizotomy for children with spasticity
Description: Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
Study: NCT02075242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),
Study: NCT01851642

Intervention type: PROCEDURE
Intervention: History and physical exam.
Description: At every study visit, participant's will be asked about their medical history and will have a physical exam.

Intervention type: PROCEDURE
Intervention: Blood draw.
Description: At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.

Intervention type: PROCEDURE
Intervention: Blood draw.
Description: At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
Study: NCT02075242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
Study: NCT00979706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART + Immunotherapy
Description: Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year.
Study: NCT02679014

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5459072
Description: With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
Study: NCT00299052

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grafton DBM
Description: Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reamings
Description: Bone reamings obtained during tibia IMN will be placed at the fracture site
Study: NCT03339388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced Lithotripsy System
Description: Stone treatment with the Enhanced Lithotripsy System
Study: NCT00161187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
Study: NCT01210807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One-Piece Tecnis Multifocal IOL
Description: One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: One-Piece Tecnis monofocal IOL, Model ZCB00
Description: Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
Study: NCT00516048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Study: NCT00639691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: sc
Study: NCT04680728

Intervention type: OTHER
Intervention: collection of biological parameters
Description: haemoglobin, haematocrit, sodium, chloraemia, total protein, albumin, L-lactate, pro-BNP, creatinine, uremia, AST, ALT, GGT, ALP, bilirubin, prothrombin time, urinary test if available.

Intervention type: OTHER
Intervention: collection of echographic parameters
Description: echocardiography (FEVG, subaortic ITV before and after LJP, cardiac index, MAPSE, mitral flow doppler, RVFAC, FEVD, STDVD, VD/VG ratio, TAPSE, tricuspid S wave, IT with PAPs, tricuspid flow doppler), Doppler of suprahepatic veins (S wave, D wave, S/D ratio), renal doppler (VII, RRI, aspect of venous flow in cortical and hilar), femoral venous doppler, doppler of the portal trunk, diameter of the VCI.

Intervention type: OTHER
Intervention: collection of clinical parameters
Description: eason for hospitalisation, co-morbidities, IGS2 score, SOFA, haemodynamic signs (BP, HR, CVP), sinus rhythm or not, temperature, diuresis, weight, input-output assessment, use of dialysis, ventilatory parameters (intubation, mode, FiO2(%), Vt, FR, PEEP, plateau pressure, driving pressure), state of shock (sepsis, postoperative, haemorrhagic, cardiogenic), transfusion (type, number), catecholamines (type, dose, duration), diuretics and dose, clinical criteria of venous congestion (jugular turgidity, hepato-jugular reflux, hepatosplenomegaly, pitting oedemas of the lower limbs, hepatalgia), neurological evaluation (Glasgow Coma Scale, CAM-ICU), time to resume enteral feeding and bowel movements, weight.
Study: NCT02556502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben PET
Study: NCT01188200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental nutritional formula #M979
Description: One two hundred and forty mL serving at test time, taken orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard food
Description: Standard meal prior to test time
Study: NCT03439436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xylo+dex nasal spray (0.1 mg+5 mg/dose)
Description: Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasic
Description: Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
Study: NCT02665169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise
Description: Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health counselling
Description: Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health counselling
Description: Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
Study: NCT01775332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.
Study: NCT03281668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Each training session for High Intensity Interval Training will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
Study: NCT02106286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Study: NCT02361450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retrograde Colonic Irrigation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT01516970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir (DRV/r)
Description: Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir in fixed combination with Ritonavir
Description: type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRTIs
Description: The NRTIs (including tenofovir/emtricitabine \[Truvada\], lamivudine/zidovudine \[Combivir\]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: The NRTIs (including tenofovir/emtricitabine \[Truvada\], lamivudine/zidovudine \[Combivir\]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
Study: NCT00956774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HSG with acorn-tipped cannula
Description: Use of acorn-tipped cannula for HSG to evaluate tubal patency

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HSG with cervical vacuum cup
Description: cup placed over cervix to create vacuum pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HSG with balloon catheter
Description: balloon inserted via catheter into cervic for dilation.
Study: NCT02667275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Placebo
Study: NCT01487642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard 15-minute telephone counselling
Description: Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive telephone counselling
Description: subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive telephone counselling
Description: subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive web-based smoking cessation programme
Description: Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-help material
Description: Participants receives self-help materials and on request information on other smoking cessation services if they wish.
Study: NCT01756040

Intervention type: DRUG
Group type: OTHER
Intervention: Lactulose -rhamnose solution
Description: Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
Study: NCT02834169

Intervention type: OTHER
Intervention: Non interventional
Description: Data collection

Intervention type: OTHER
Intervention: Non interventional
Description: Data collection

Intervention type: OTHER
Intervention: Non interventional
Description: Data collection

Intervention type: OTHER
Intervention: Non interventional
Description: Data collection

Intervention type: OTHER
Intervention: Non interventional
Description: Data collection

Intervention type: OTHER
Intervention: Non interventional
Description: Data collection

Intervention type: OTHER
Intervention: Non interventional
Description: Data collection
Study: NCT00130702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: gefitinib (Iressa) at a dose of 750 mg, once per day
Study: NCT02538016

Intervention type: DRUG
Group type: OTHER
Intervention: Tolvaptan
Study: NCT04543799

Intervention type: DEVICE
Intervention: polysomnography, actigraphy, questionnaires
Description: sleep quality recording

Intervention type: DEVICE
Intervention: polysomnography, actigraphy, questionnaires
Description: sleep quality recording

Intervention type: DEVICE
Intervention: polysomnography, actigraphy, questionnaires
Description: sleep quality recording

Intervention type: DEVICE
Intervention: polysomnography, actigraphy, questionnaires
Description: sleep quality recording
Study: NCT01110616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally
Study: NCT01851642

Intervention type: PROCEDURE
Intervention: Blood draw.
Description: At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.

Intervention type: PROCEDURE
Intervention: Pulmonary function testing.
Description: At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.

Intervention type: PROCEDURE
Intervention: Pulmonary function testing.
Description: At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.

Intervention type: PROCEDURE
Intervention: Pulmonary function testing.
Description: At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.

Intervention type: DRUG
Intervention: Albuterol inhaler.
Description: At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.

Intervention type: DRUG
Intervention: Albuterol inhaler.
Description: At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.

Intervention type: DRUG
Intervention: Albuterol inhaler.
Description: At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
Study: NCT01745458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SB-659032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo